- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Regenxbio Inc (RGNX)
Regenxbio Inc stock price live, this page displays NASDAQ RGNX stock exchange data. View the RGNX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Regenxbio Inc real time stock price chart below.
What Is the Regenxbio Inc Stock Price Today?
The Regenxbio Inc stock price today is 9.69.
What Is the Stock Symbol for Regenxbio Inc?
The stock symbol for Regenxbio Inc is "RGNX."
What Stock Exchange Does Regenxbio Inc Trade On?
Regenxbio Inc is listed and trades on the NASDAQ stock exchange.
Is Regenxbio Inc a Good Stock to Buy?
Determining whether Regenxbio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGNX quote. (ISIN: US75901B1070)
What Is the Regenxbio Inc Stock Price Today?
The Regenxbio Inc stock price today is 9.69.
What Is the Stock Symbol for Regenxbio Inc?
The stock symbol for Regenxbio Inc is "RGNX."
What Stock Exchange Does Regenxbio Inc Trade On?
Regenxbio Inc is listed and trades on the NASDAQ stock exchange.
Is Regenxbio Inc a Good Stock to Buy?
Determining whether Regenxbio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGNX quote. (ISIN: US75901B1070)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.64
10.38
52 wk Range
5.46
16.19
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.6410.38
52 wk Range
5.4616.19
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RGNX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
24.27
Upside
+150.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 424B5 Regenxbio Inc For: 17 July- Investing.com
- Form 424B5 Regenxbio Inc For: 17 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 24.27
(+150.49% Upside)
Regenxbio Inc SWOT Analysis
Gene Therapy Pionee | REGENXBIO's innovative AAV platform targets genetic and rare diseases, with promising developments in DMD, wet AMD, and MPS II treatments |
DMD Market Potential | Explore REGENXBIO's RGX-202 gene therapy for Duchenne muscular dystrophy, offering higher expression levels and broader patient eligibility than competitors |
Ocular Breakthroughs | Delve into REGENXBIO's partnership with AbbVie for ocular gene therapies, with pivotal trials and BLA submissions expected in the near future |
Financial Outlook | Analyst price targets range from $13 to $52, suggesting significant upside potential despite current unprofitability and a market cap of $487 million |
Regenxbio Inc Earnings Call Summary for Q4/2025
- Q4 2025 EPS of -$1.30 missed forecast of -$0.72; revenue of $30.34M fell short of expected $59.28M, triggering 9.19% stock decline.
- Company maintains $241M cash position; expects $100M AbbVie milestone payment in Q2 2026, extending runway into H2 2027.
- Heavy R&D investment continues in gene therapy programs RGX-202 for DMD and RGX-314 for retinal diseases; pivotal data due early Q2 2026.
- Regulatory challenges persist for Mucopolysaccharidosis programs with recent clinical holds; no specific guidance provided for these initiatives.
- Stock down 36.5% YTD to $8.88; analysts maintain bullish outlook with price targets of $12-$50 despite near-term setbacks.
Last Updated: 2026-03-05, 09:32 a/m
Read Full TranscriptEarnings
Latest Release
May 14, 2026
EPS / Forecast
-1.72 / -1.34
Revenue / Forecast
6.39M / 25.8M
Compare RGNX to Peers and Sector
Metrics to compare | RGNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRGNXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −2.9x | −0.3x | |
PEG Ratio | 0.03 | −0.05 | 0.00 | |
Price/Book | 28.4x | 1.9x | 2.6x | |
Price / LTM Sales | 6.8x | 49.4x | 3.0x | |
Upside (Analyst Target) | 87.7% | 146.6% | 56.6% | |
Fair Value Upside | Unlock | 2.2% | 10.2% | Unlock |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Regenxbio Inc (RGNX) Stock Price Today?
The Regenxbio Inc stock price today is 9.69 USD.
What Stock Exchange Does Regenxbio Inc Trade On?
Regenxbio Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Regenxbio Inc?
The stock symbol for Regenxbio Inc is "RGNX."
What Is the Regenxbio Inc Market Cap?
As of today, Regenxbio Inc market cap is 624.43M USD.
What Is Regenxbio Inc's Earnings Per Share (TTM)?
The Regenxbio Inc EPS (TTM) is -5.60.
When Is the Next Regenxbio Inc Earnings Date?
Regenxbio Inc will release its next earnings report on Aug 05, 2026.
From a Technical Analysis Perspective, Is RGNX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Regenxbio Inc Stock Split?
Regenxbio Inc has split 0 times.
How Many Employees Does Regenxbio Inc Have?
Regenxbio Inc has 371 employees.
What is the current trading status of Regenxbio Inc (RGNX)?
As of Jul 31, 2026, Regenxbio Inc (RGNX) is trading at a price of 9.69 USD, with a previous close of 10.12 USD. The stock has fluctuated within a day range of 9.64 USD to 10.38 USD, while its 52-week range spans from 5.46 USD to 16.19 USD.
What Is Regenxbio Inc (RGNX) Price Target According to Analysts?
The average 12-month price target for Regenxbio Inc is 24.27 USD, with a high estimate of 50 USD and a low estimate of 10 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +150.49% Upside potential.
What Is the RGNX Premarket Price?
RGNX's last pre-market stock price is 10.11 USD. The pre-market share volume is 1,520.00, and the stock has decreased by -0.01, or -0.10%.
What Is the RGNX After Hours Price?
RGNX's last after hours stock price is 9.88 USD, the stock has decreased by 0.19, or 1.96%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.